Trial Profile
Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Somatostatins (Primary) ; Sorafenib (Primary)
- Indications Liver cancer; Neuroendocrine tumours
- Focus Therapeutic Use
- 27 Apr 2021 Status changed from recruiting to completed.
- 29 Nov 2016 New trial record